Biora Therapeutics Stock Quote BIOR - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.649

Bid

0.62

Ask

0.65

Volume

357,985

0.5803 Day's Range 0.666499

0.00 52 Week Range 0.00

Market Cap

22.607M

Previous Close

0.66

Open

0.66

Last Trade

100

0.649

(formt)

Last Trade Time

17:54:16

Financial Volume

$ 225,478

VWAP

0.629854

Average Volume (3m)

Shares Outstanding

35,883,843

Dividend Yield

PE Ratio

-0.18

Earnings Per Share (EPS)

-3.46

Revenue

Net Profit

-124.12M

Progenity Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Progenity Inc is primarely in the business of services-medical laboratories. For financial reporting their fiscal year ends on December 31st. This page includes all SEC registration de... Progenity Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Progenity Inc is primarely in the business of services-medical laboratories. For financial reporting their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents S-1 Prospectus Current Reports 8-K 10K Annual Reports filed by Progenity Inc.. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.bicara.com

Headquarters

Dover, Delaware, USA

Founded

1970

Biora Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BIOR. The last closing price for Biora Therapeutics was $0.66. Over the last year, Biora Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Biora Therapeutics currently has 35,883,843 shares outstanding. The market capitalization of Biora Therapeutics is $22.61 million. Biora Therapeutics has a price to earnings ratio (PE ratio) of -0.18.

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600

Drug-device combination leverages Biora’s NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all...

Form 8-K - Current report

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
RDZNRoadzen Inc	$ 2.57 (58.64%)	2.77M
VSVersus Systems Inc	$ 1.76 (33.33%)	822.91k
AWHAspira Womans Health Inc	$ 1.18 (19.19%)	310.63k
IINNInspira Technologies Oxy B H N Ltd	$ 1.44 (18.03%)	3.48k
VEVVicinity Motor Corporation	$ 0.63 (17.74%)	610
CONNConns Inc	$ 0.66 (-36.54%)	302.71k
BWAQBlue World Acquisition Corporation	$ 2.78 (-34.43%)	186.63k
NUKKNukkleus Inc	$ 0.36 (-15.11%)	181.94k
DAREDare Bioscience Inc	$ 3.30 (-12.93%)	759
LGHLWLion Group Holding Ltd	$ 0.0073 (-12.05%)	11.79k
OXLCOxford Lane Capital Corporation	$ 5.43 (0.37%)	7.72M
PRSTPresto Technologies Inc	$ 0.0937 (-3.80%)	3.79M
NVDANVIDIA Corporation	$ 123.96 (-0.27%)	3.36M
SNTISenti Biosciences Inc	$ 0.395 (-5.39%)	3.3M
RDZNRoadzen Inc	$ 2.57 (58.64%)	2.77M